Benitec Biopharma (NASDAQ:BNTC – Get Free Report) had its price objective raised by investment analysts at Wedbush from $17.00 to $20.00 in a report released on Monday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Wedbush‘s target price indicates a potential upside of 121.24% from the stock’s previous close.
Several other research firms also recently issued reports on BNTC. Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, October 6th. Raymond James Financial initiated coverage on shares of Benitec Biopharma in a research note on Friday, October 23rd. They issued an “outperform” rating and a $14.00 target price on the stock. Wall Street Zen lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Royal Bank Of Canada raised shares of Benitec Biopharma to an “outperform” rating in a research report on Tuesday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Benitec Biopharma has an average rating of “Moderate Buy” and an average target price of $22.75.
Read Our Latest Stock Analysis on BNTC
Benitec Biopharma Stock Performance
BNTC opened at $9.04 on Monday. The firm has a 50 day moving average price of $9.67 and a 200 day moving average price of $11.39. The company has a market cap of $315.41 million, a PE ratio of -8.86 and a beta of 0.26. Benitec Biopharma has a 1 year low of $7.89 and a 1 year high of $14.39.
Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. On average, sell-side analysts predict that Benitec Biopharma will post -1.35 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in BNTC. AWM Investment Company Inc. purchased a new position in shares of Benitec Biopharma in the second quarter valued at $2,515,000. Bank of New York Mellon Corp purchased a new stake in Benitec Biopharma during the 2nd quarter worth $804,000. Nantahala Capital Management LLC increased its stake in Benitec Biopharma by 12.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,677,567 shares of the biotechnology company’s stock worth $16,776,000 after buying an additional 189,196 shares during the period. Bank of America Corp DE increased its stake in Benitec Biopharma by 43.3% during the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after buying an additional 5,251 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Benitec Biopharma by 18.7% in the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock worth $107,000 after buying an additional 1,256 shares in the last quarter. 52.19% of the stock is owned by institutional investors and hedge funds.
About Benitec Biopharma
Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.
Further Reading
- Five stocks we like better than Benitec Biopharma
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
